Thrivent Financial for Lutherans Reduces Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Thrivent Financial for Lutherans lessened its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 19.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 115,965 shares of the medical research company’s stock after selling 27,938 shares during the quarter. Thrivent Financial for Lutherans owned about 0.09% of Natera worth $18,357,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Blue Trust Inc. grew its stake in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after buying an additional 97 shares during the last quarter. Versant Capital Management Inc grew its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of Natera by 372.9% in the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after acquiring an additional 261 shares during the period. Principal Securities Inc. raised its position in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 59 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in Natera during the 3rd quarter worth $57,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Up 1.0 %

Natera stock opened at $151.15 on Friday. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The firm has a market capitalization of $20.43 billion, a price-to-earnings ratio of -85.88 and a beta of 1.80. The stock’s fifty day moving average is $161.23 and its two-hundred day moving average is $149.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.01. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the subject of a number of research reports. Sanford C. Bernstein upped their target price on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a report on Friday, January 10th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $180.00 price objective on shares of Natera in a research note on Wednesday, February 26th. Piper Sandler lifted their target price on Natera from $200.00 to $205.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. JPMorgan Chase & Co. upped their price target on Natera from $160.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Finally, The Goldman Sachs Group lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $178.12.

Insider Activity at Natera

In related news, CEO Steven Leonard Chapman sold 6,702 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $146.03, for a total value of $978,693.06. Following the completion of the transaction, the chief executive officer now owns 203,354 shares of the company’s stock, valued at approximately $29,695,784.62. The trade was a 3.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 1,026 shares of the firm’s stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $146.04, for a total transaction of $149,837.04. Following the sale, the insider now directly owns 144,782 shares in the company, valued at $21,143,963.28. This represents a 0.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 307,466 shares of company stock valued at $49,047,655. 7.60% of the stock is owned by corporate insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.